# Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

Study · id `cardio:ct-nct07687485` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07687485](<https://clinicaltrials.gov/study/NCT07687485>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07687485

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 700 participants.

## Technical summary

Registry record NCT07687485. Randomized; single masking; primary purpose treatment. Start 2026-09-04 (actual); primary completion 2029-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 700 participants (planned count; ClinicalTrials.gov record NCT07687485, source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)
- Started: 2026-09-04 (actual) (ClinicalTrials.gov record NCT07687485, source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07687485, source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)
- Completion: 2038-09 (anticipated) (ClinicalTrials.gov record NCT07687485, source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07687485, source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07687485-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System
- Acronym: TRIUMPH
- Condition: Severe Tricuspid Valve Regurgitation
- Condition: Tricuspid Valve Regurgitation
- Condition: Tricuspid Valve Disease
- Condition: Cardiovascular Diseases (CVD)
- Condition: Heart Valve Diseases
- Condition: Tricuspid Valve Insufficiency
- Condition: Severe Heart Valve Disease
- Condition: Symptomatic Tricuspid Regurgitation
- Intervention (Device): Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System
- Intervention (Device): Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System
- Lead sponsor: Laplace Interventional, Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: 8a6dc64b702928805906245433e15c155997c92a7971160b30785fb8ed65ab38
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
